# AnHorn Medicines

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/anhorn-medicines
Canonical HTML page: https://getbiobrief.com/entity/anhorn-medicines

## Recent coverage (1 stories)

### With 0 Approved Drugs for CIPN, AH-008’s IND Clearance Opens First-in-Class Trial Path
2026-07-25 13:23:42 · Sentiment: Bullish · Impact: 7/10 · Sources: 1

AnHorn Medicines’ neuroprotective candidate AH-008 cleared FDA IND and received Taiwan CDE Index Case status, advancing into human trials for chemotherapy-induced peripheral neuropathy, a condition with zero approved preventive therapies.
Full story: https://getbiobrief.com/story/ah-008-fda-ind-cipn-prevention-zero-approved-drugs

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.